Ruxolitinib: Long-Term Management of Patients with Myelofibrosis and Future Directions in the Treatment of Myeloproliferative Neoplasms
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ruxolitinib: Long-Term Management of Patients with Myelofibrosis and Future Directions in the Treatment of Myeloproliferative Neoplasms
Authors
Keywords
Allogeneic stem cell transplantation, COMFORT-I, COMFORT-II, JAK inhibitor, Myelofibrosis, Myeloproliferative neoplasm, Polycythemia vera, Ruxolitinib, Splenomegaly
Journal
Current Hematologic Malignancy Reports
Volume 9, Issue 4, Pages 350-359
Publisher
Springer Nature
Online
2014-08-21
DOI
10.1007/s11899-014-0229-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts
- (2014) F. Passamonti et al. BLOOD
- Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study
- (2014) P. Guglielmelli et al. BLOOD
- Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
- (2014) R. Rampal et al. BLOOD
- Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
- (2014) P. Lundberg et al. BLOOD
- Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
- (2014) S. Spoerl et al. BLOOD
- Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
- (2014) F. Lussana et al. HAEMATOLOGICA
- Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment
- (2014) Lana X. Tong et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis
- (2014) T Stübig et al. LEUKEMIA
- Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis
- (2014) A Tabarroki et al. LEUKEMIA
- CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
- (2014) A Tefferi et al. LEUKEMIA
- Disseminated tuberculosis associated with ruxolitinib
- (2014) R K Hopman et al. LEUKEMIA
- Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis
- (2014) Danijela Lekovic et al. MEDICAL ONCOLOGY
- JAK Inhibitor in CALR-Mutant Myelofibrosis
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms
- (2013) T. Tadmor et al. AMERICAN JOURNAL OF HEMATOLOGY
- Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis
- (2013) Heinz Gisslinger et al. AMERICAN JOURNAL OF HEMATOLOGY
- The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
- (2013) A. Heine et al. BLOOD
- Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
- (2013) N Jaekel et al. BONE MARROW TRANSPLANTATION
- Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinibversusbest available therapy
- (2013) Claire N. Harrison et al. BRITISH JOURNAL OF HAEMATOLOGY
- The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
- (2013) Srdan Verstovsek et al. BRITISH JOURNAL OF HAEMATOLOGY
- Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm
- (2013) Santiago Barrio et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)
- (2013) John Mascarenhas et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
- (2013) Srdan Verstovsek et al. CANCER
- An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor
- (2013) Nicholas G. Wysham et al. CHEST
- JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease
- (2013) E. Evrot et al. CLINICAL CANCER RESEARCH
- What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?
- (2013) Fabio P.S. Santos et al. CURRENT OPINION IN HEMATOLOGY
- Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
- (2013) S. Verstovsek et al. HAEMATOLOGICA
- JAK inhibitors: beyond spleen and symptoms?
- (2013) F. Cervantes et al. HAEMATOLOGICA
- Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib
- (2013) B. S. Wilkins et al. HAEMATOLOGICA
- Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2013) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing
- (2013) Ruben A Mesa et al. Journal of Hematology & Oncology
- Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
- (2013) Moshe Talpaz et al. Journal of Hematology & Oncology
- Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis
- (2013) G Caocci et al. LEUKEMIA
- Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib
- (2013) M Massa et al. LEUKEMIA
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
- (2013) A Pardanani et al. LEUKEMIA
- Mutations and prognosis in primary myelofibrosis
- (2013) A M Vannucchi et al. LEUKEMIA
- Epidemiology of myeloproliferative neoplasms in the United States
- (2013) Jyotsna Mehta et al. LEUKEMIA & LYMPHOMA
- Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study
- (2013) Ruben A. Mesa et al. LEUKEMIA RESEARCH
- Modest activity of pomalidomide in patients with myelofibrosis and significant anemia
- (2013) Naval Daver et al. LEUKEMIA RESEARCH
- Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
- (2013) Srdan Verstovsek et al. LEUKEMIA RESEARCH
- Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib
- (2013) Rowan Wathes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML
- (2013) Julia E. Maxson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis
- (2013) Sonja Burgstaller et al. WIENER KLINISCHE WOCHENSCHRIFT
- Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
- (2013) Srdan Verstovsek et al. OncoTargets and Therapy
- Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly
- (2012) O. Benjamini et al. BLOOD
- Risk models predicting survival after reduced-intensity transplantation for myelofibrosis
- (2012) Haefaa Alchalby et al. BRITISH JOURNAL OF HAEMATOLOGY
- Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis
- (2012) Alfonso Quintás-Cardama et al. LEUKEMIA RESEARCH
- One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
- (2012) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis
- (2012) Umberto Gianelli et al. MODERN PATHOLOGY
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic and Epigenetic Complexity in Myeloproliferative Neoplasms
- (2011) N. C. P. Cross Hematology-American Society of Hematology Education Program
- Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms
- (2010) S. T. Oh et al. BLOOD
- PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis
- (2010) J.S. Duffield et al. DRUG NEWS & PERSPECTIVES
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- MPN-associated myelofibrosis (MPN-MF)
- (2010) R.A. Mesa et al. LEUKEMIA RESEARCH
- Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment
- (2010) Vivian Barry-Hamilton et al. NATURE MEDICINE
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type
- (2009) A Bacigalupo et al. BONE MARROW TRANSPLANTATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now